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Radial Access for ST-Segment
Elevation Myocardial Infarction
Interventions
Does It Really Lower Mortality?*
Ehtisham Mahmud, MD, Mitul Patel, MD
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Although the radial access option has existed for over
20 years, only recently has it been adopted for coronary
angiography and percutaneous coronary intervention (PCI)
in the United States. Despite the recent enthusiasm for
this approach, only 16.1% of PCI procedures in the
United States are performed radially (1), and it has been
suggested that with experienced operators, the radial or
femoral approach leads to comparable clinical outcomes (2).
Furthermore, at least in the United States, limited radial
access training has resulted in the majority of interventional
cardiologists being unfamiliar with radial access and, there-
fore, they have failed to embrace this technique (2). In
contrast, outside of the United States, most intervention-
alists have adopted the radial approach as the predominant
access for PCI (3).
See page 814
In acute ST-segment elevation myocardial infarction
(STEMI) patients, timely reperfusion is the primary goal,
and the femoral approach would appear to provide the
advantages of rapid arterial access, more predictable vascular
anatomy, and the ability to provide supplemental hemody-
namic support as necessary. However, in STEMI patients
there is also greater use of potent adjunctive anticoagulation
and antiplatelet therapy, potentially leading to higher
bleeding rates, which in turn are associated with adverse
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site for PCI patients, a recently published randomized
controlled trial (RCT) of radial versus femoral approach
for primary PCI in STEMI patients showed signiﬁcant
reductions in major adverse cardiac events (MACE)
including cardiac mortality in favor of the radial approach (7).
Karrowni et al. expand on the results of this single
study in the meta-analysis published in the current issue
of JACC: Cardiovascular Interventions (8). Analyzing the
published and presented RCT (n ¼ 12) of STEMI patients
(n ¼ 5,055) randomized to the radial versus femoral
approach, they show that radial access leads to superior
outcomes with reductions in both mortality and major
bleeding. Statistically, the dataset was homogeneous with
consistent and pertinent endpoints, and matched anti-
coagulation and antiplatelet therapies. Their analysis
revealed signiﬁcant reductions in mortality (2.7% vs. 4.7%;
odds ratio [OR]: 0.55, 95% conﬁdence interval [CI]: 0.40 to
0.76; p < 0.001), major bleeding (1.4% vs. 2.9%; OR: 0.51,
95% CI: 0.31 to 0.85; p ¼0.01), access site bleeding (2.1%
vs. 5.6%; OR: 0.35, 95% CI: 0.25 to 0.50; p < 0.001), and
overall MACE (4.6% vs. 6.8%; OR: 0.64, 95% CI: 0.49 to
0.83; p < 0.001) with the radial approach. No differences
were observed in the incidence of stroke, myocardial
infarction, or target lesion or target vessel revascularization.
Procedure time was minimally prolonged in the radial arm
by 1.5 min (p ¼ 0.01), whereas crossover rates were 4.6%
with the radial and 1.1% with the femoral approach.
The reduction in ischemic time and mortality for STEMI
patients treated with primary PCI (using the femoral
approach in the majority of studies) is well documented and
has resulted in this being the preferred reperfusion strategy
(9,10). The current study suggests that an additional
incremental lowering of mortality using the radial approach
in STEMI patients, beyond that previously achieved with
early mechanical reperfusion using the femoral approach, is
possible without a delay in the procedure time. However,
these mortality data need to be interpreted with caution. A
meta-analysis to deﬁne an optimal treatment strategy is
often performed when prior data are incongruent, or in the
absence of an adequately powered multicenter RCT. In the
current meta-analysis, mortality data are heavily weighted
from 3 studies: the STEMI cohort from RIVAL (Radial
Versus Femoral Access for Coronary Intervention Trial)
(n ¼ 1,958) (11); RIFLE-STEACS (Radial Versus Femoral
Randomized Investigation in ST-Elevation Acute Coronary
Syndrome) (n ¼ 1,001) (7); and the STEMI-RADIAL
(A Prospective Randomized Trial of Radial vs. Femoral
Access in Patients With ST-Segment Elevation Myocardial
Infarction) trial (n ¼ 707) (12). The STEMI cohort in
RIVAL was a subgroup analysis of a larger trial that failed to
demonstrate a difference in major bleeding or ischemic
events between the radial and femoral approach in 7,021
patients with an acute coronary syndrome. The majority of
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825deaths were in patients who did not have a major bleed or an
access site complication (11), and the results from
a subgroup analysis should always be interpreted with
caution. In RIFLE-STEACS, a 4-center clinical trial per-
formed in Italy at high-volume radial access centers, patients
presenting up to 24 h after their index event or in cardio-
genic shock were included, and the majority of patient
deaths were from pump failure and not related to access site
complications or bleeding (7). Both RIVAL and RIFLE-
STEACS also included patients who underwent rescue PCI
after failed thrombolysis. In contrast, the STEMI-RADIAL
trial had the strictest inclusion criteria, with patients
undergoing primary PCI within 12 h of symptom onset, and
despite signiﬁcant reduction in bleeding and access site
complications with radial access, this study did not demon-
strate a mortality difference between the 2 approaches (12).
Therefore, individually evaluating the 3 major studies
included in this meta-analysis shows signiﬁcant heterogeneity
in inclusion criteria and the lack of a mechanistic link between
individual patient access site complications, bleeding, and
mortality. At best, these data are hypothesis-generating and
are awaiting conﬁrmation from a large, adequately powered,
multicenter RCT.
Anticoagulation strategies with low use of the direct
thrombin inhibitor bivalirudin (<10% in the included
studies) and higher than contemporary use of glycoprotein
IIb/IIIa inhibitors (30% to 70% in the included studies) also
favored the radially treated patients when considering access
site bleeding as an endpoint and might have contributed
to the mortality difference in the 2 groups (7,8,11,12). A
contemporary strategy of thienopyridine pre-treatment,
judicious use of glycoprotein IIb/IIIa inhibitors, and routine
bivalirudin use for STEMI patients as part of a bleeding
avoidance strategy might lead to a less signiﬁcant difference
in bleeding rates with the femoral approach. However, until
such an approach is tested, the radial approach is clearly
associated with lower access site complications and major
bleeding, and the data are consistent in all of the trials
included. The association between bleeding and long-term
adverse events after PCI is well established, though secondary
transfusion and premature discontinuation of adjunctive
pharmacotherapy for hemodynamically unstable patients
after a bleeding event are likely among the contributing
factors (4–6).
The deﬁnition of MACE and length of follow-up for
clinical events was highly variable in the studies included and
the lower MACE rate seen with the radial approach was
primarily a result of the mortality beneﬁt observed in the
RIVAL (STEMI cohort) and RIFLE-STEACS studies.
Individual MACE rates were comparable with both access
strategies. Notably, data regarding the reduction in bleeding
and mortality with radial access in the current analysis
are also consistent with a recent large ACC-NCDR
(American College of Cardiology–National CardiovascularData Registry) database analysis showing lower bleeding and
in-hospital mortality with radial access PCI during STEMI
(13). However, in order to replicate these ﬁndings in clinical
practice, primary PCI for STEMI using radial access
requires experienced operators at high-volume radial cathe-
terization laboratories. This was common in all of the studies
included, and though exact deﬁnition of an experienced
radial operator is unclear, a steep radial access learning curve
is well recognized.
To achieve uniform proﬁciency in this technique, we have
to: 1) ensure that radial access is a formal part of all training
programs in interventional cardiology; 2) provide high-
quality radial access training programs throughout the
country for practicing interventional cardiologists; 3)
promote a change of culture in catheterization labs so that
staff are also engaged and trained; and 4) engage regional
proctors/experts who can rapidly disseminate the technique
to enable the majority of interventional cardiologists
managing STEMI patients in becoming facile with radial
access. This should lower access site bleeding and has the
potential to further lower mortality rates in STEMI patients.
Based on the current data, the radial approach to PCI in
STEMI patients appears to be the preferred approach for
experienced radial operators. However, in the absence of
adequate training in radial access, primary PCI operators and
centers should perfect the radial access approach in elective
PCI patients prior to routinely using it in STEMI patients.
Additional beneﬁts of using the radial approach, including
improved patient comfort, efﬁcient catheterization lab
throughput, and easier same day discharge, particularly
applies to elective PCI patients in whom a mortality beneﬁt
likely does not exist or would be impossible to demonstrate.
An adequately powered, multicenter RCT for STEMI
patients testing radial versus femoral access with contempo-
rary antiplatelet and anticoagulation strategy, and routine
vascular closure device for the femoral access, is imperative to
determine if a mortality beneﬁt truly exists with the radial
approach and to further explore the relation between access
site, bleeding, MACE, and mortality.
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